Roche obtains license for EGFR lung cancer assays and will develop Tarceva companion diagnostic test
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has obtained a worldwide sublicense from Genzyme Corporation to develop a diagnostic assay for the detection of Epidermal Growth-Factor Receptor (EGFR) mutations.
Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies with VEGF Trap-Eye
- Details
- Category: Bayer
Bayer HealthCare and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint.
Abbott Announces Positive Results from Phase 2 Study of Low Dose Atrasentan for Treatment of Diabetic Kidney Disease
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced positive results from a Phase 2 dose-ranging study of atrasentan, a highly selective endothelin A receptor antagonist in development to help slow chronic kidney disease (CKD) progression in patients with type 2 diabetic nephropathy (diabetic kidney disease).
APPRAISE-2 Study with Investigational Compound Apixaban Discontinued
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) reported that the companies have discontinued the Phase 3 APPRAISE-2 clinical trial in patients with recent Acute Coronary Syndrome (ACS) treated with apixaban or placebo in addition to mono or dual antiplatelet therapy.
Novartis unveils long-term strategy to grow in a dynamically changing healthcare environment
- Details
- Category: Novartis
Novartis presented a strategic overview of the company's diversified healthcare portfolio which creates the potential for future sustainable growth. The company's focused healthcare portfolio across key growth segments in healthcare provides Novartis a leading position in the respective market segments.
Genzyme Announces Agreement to Sell Diagnostics Business
- Details
- Category: Genzyme
Genzyme Corporation (Nasdaq: GENZ) announced that it has entered into an asset purchase agreement under which Sekisui Chemical Co., Ltd. will acquire Genzyme's Diagnostic products business for $265 million in cash.
Pfizer Launches Global Centers for Therapeutic Innovation
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced the establishment of the Global Centers for Therapeutic Innovation, an entrepreneurial network of partnerships with leading academic medical centers to transform research and development by accessing leading translational researchers.
More Pharma News ...
- Roche announces implementation plans for its Operational Excellence Program
- Boehringer Ingelheim steps up to the challenge in support of World Diabetes Day
- Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity
- Rivaroxaban Significantly Reduces Risk of Stroke with Comparable Safety versus Warfarin
- Diabetes awareness survey reveals alarming figures across the Middle East and Northern Africa regions
- Collaboration of Boehringer Ingelheim and VTU Technology
- Bristol-Myers Squibb Foundation Launches $100 Million Initiative Targeting America's Type 2 Diabetes Crisis